BiotechTube

Tetrabenazine

ApprovedUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Huntington's Disease

Conditions

Huntington's Disease

Trial Timeline

Aug 1, 2018 → Jul 1, 2023

NCT ID
NCT02509793

About Tetrabenazine

Tetrabenazine is a approved stage product being developed by Lundbeck for Huntington's Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT02509793. Target conditions include Huntington's Disease.

What happened to similar drugs?

0 of 1 similar drugs in Huntington's Disease were approved

Approved (0) Terminated (1) Active (0)
❌SAGE-718Supernus PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
20
Activity
4
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02509793ApprovedUNKNOWN

Competing Products

15 competing products in Huntington's Disease

See all competitors
ProductCompanyStageHype Score
AFQ056 + PlaceboNovartisPhase 2
27
RO7234292 (RG6042)RochePhase 2
35
RG6496 + PlaceboRochePhase 1
36
PF-02545920 + PF-02545920PfizerPhase 2
35
20 mg BID of PF-02545920PfizerPhase 2
27
PF-02545920 + Placebo + PF-02545920 + PlaceboPfizerPhase 2
35
ALN-HTT02 + PlaceboAlnylam PharmaceuticalsPhase 1
33
BN82451B + PlaceboIpsenPhase 2
24
ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mgIonis PharmaceuticalsPhase 1/2
29
WVE-120102 + PlaceboWaVe Life SciencesPhase 1/2
18
WVE-120101 + PlaceboWaVe Life SciencesPhase 1/2
18
SAGE-718Supernus PharmaceuticalsPhase 3
26
SAGE-718 + PlaceboSupernus PharmaceuticalsPhase 2
29
OMS643762 + PlaceboOmeros CorporationPhase 2
21
VX15/2503 + PlaceboVaccinexPhase 2
25